Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at B. Riley Financial

B. Riley Financial reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Monday,Benzinga reports. B. Riley Financial currently has a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $17.00.

Other research analysts have also issued research reports about the company. HC Wainwright dropped their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Monday. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $13.70.

Vanda Pharmaceuticals Trading Up 5.3%

VNDA opened at $5.19 on Monday. The stock has a 50-day moving average of $5.71 and a 200 day moving average of $6.69. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12 month low of $4.27 and a 12 month high of $9.94. The firm has a market cap of $313.80 million, a P/E ratio of -1.12 and a beta of 0.64.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The firm had revenue of $50.53 million during the quarter, compared to analysts’ expectations of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, research analysts forecast that Vanda Pharmaceuticals will post -3 EPS for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in Vanda Pharmaceuticals by 34.3% in the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 14,232 shares in the last quarter. Millennium Management LLC raised its stake in shares of Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after acquiring an additional 1,470,898 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Vanda Pharmaceuticals by 17.6% during the second quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 9,960 shares in the last quarter. Norges Bank purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $543,000. Finally, Walleye Capital LLC boosted its holdings in shares of Vanda Pharmaceuticals by 155.1% in the second quarter. Walleye Capital LLC now owns 94,298 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 57,332 shares during the period. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analyst ratings remain bullish: HC Wainwright maintained a “Buy” rating and a $20 price target, while B. Riley Financial reiterated its “Buy” recommendation. These targets imply significant upside from recent trading levels. B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals
• Positive Sentiment: Psoriasis pipeline visibility: Vanda was included among psoriasis drug stocks to watch during Psoriasis Awareness Month. The company’s potential exposure to psoriasis therapies could provide an additional growth opportunity if its programs advance successfully. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Short-interest data shows no meaningful bearish positioning: Reported short interest was zero shares, with a zero-day days-to-cover ratio. However, the reported increase is mathematically invalid because the prior period also showed zero shares, making this data of limited investment value.
• Negative Sentiment: HC Wainwright significantly lowered earnings forecasts: The firm cut its FY2026 EPS estimate to a loss of $3.03 from a loss of $1.98 and reduced its FY2027 estimate to a loss of $0.94 from a loss of $0.36. Quarterly estimates were also lowered across Q3 2026 through Q4 2027, including Q3 2026 EPS of negative $0.61 and Q4 2026 EPS of negative $0.57.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.